BOZEN, Sud-Tirol, Italy, March 28, 2013 /PRNewswire/ --
Health Robotics today announced the appointment of Steve Thomas to its Board of Directors, effective immediately. Mr. Thomas spent 15 years in the Computer Industry and four years in Information Services before becoming President of Pyxis Corporation in 1997 and Group President of Cardinal Health in 1999. In 2003 he acquired Valueselling Associates, a global sales training company. Then, in 2007 he became Chairman and CEO of For Health Technologies Inc., which under his leadership pioneered efforts in the Sterile Compounding Automation sector before being acquired by Baxa Corporation and later by Baxter International.
Steve Thomas stated: "I joined the Board of Health Robotics because they have the best products in the health care industry for improving patient safety and removing real costs in the IV room. They already have the top integrated solutions in the Sterile Compounding Automation sector, and now they are poised to build a world-class company, enabling them to broaden their global impact in health care. Based on my research and health care experience, Health Robotics is very well positioned for high growth and continued market leadership for years to come."
Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "We are delighted to improve our Board's know-how with Steve Thomas. He has broad global experience in information technology, information services, health care, and sales training. He has a passion for health care innovation and has been very successful in leading high growth companies. Steve is well known to our USA customer base and will help us in taking Health Robotics to the highest possible level in recognition as the undisputed global leader in IV Automation. He has been tasked by the Board to lead the company's re-capitalization efforts and to take Health Robotics to unprecedented levels of success."
About Health Robotics:
Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing over 350 hospital installations in 5 continents with the only fully-integrated robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies, to greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput, and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug and diluent exchange errors, improve drug potency, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com
1. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.
2. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.
For additional information, please contact:
SOURCE Health Robotics